A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 2×
“Major depressive disorder (MDD) is a debilitating mental illness that affects millions of people worldwide leading to severe health and socioeconomic consequences (Kessler et al., 2003).”
BackgroundRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Another limitation of current monoamine-based antidepressants was high-lighted in the large well-known trial; sequenced treatment alternative to relieve depression (STAR n D Trial) (Rush et al., 2006a, 2006b; Trivedi et al., 2006; Nierenberg et al., (2006); Rush, 2006c; Fava et al., 2006).”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“NMDA receptors are tetrameric proteins composed of 2 NR1 subunits and 2 NR2 subunits (Dingledine et al., 1999).”
BackgroundAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 11×
“These signalling events activate mTOR (mammalian target of rapamycin), leading to increased synaptic proteins and spine densities (in preclinical studies of rat prefrontal cortices) resulting in synaptogenesis (Li et al., 2010).”
BackgroundInfluentialSüdhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“blockade of this receptor leads to less activation of eEF2 kinase which gradually results in loss of eEF2 phosphorylation and de-suppression of BDNF translation (Autry et al., 2011).”
BackgroundInfluentialMcEwen, B. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.071 · Cited by 1,864 · cited 2×
“…and spines in stress-related illnesses such as depression is supported by basic studies demonstrating that exposure to stress causes atrophy of neurons in limbic brain regions implicated in depression, including the prefrontal cortex (PFC) and hippocampus (McEwen, 2008; Shansky and Morrison, 2009).”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Using microdialysis, ketamine has been reported to increase the extracellular levels of glutamate in the prefrontal cortex of rodents (Lorrain et al., 2003; Moghaddam et al., 1997), leading to the hypothesis that hyperglutamatergic mechanisms are involved in the antidepressant effect of ketamine.”
BackgroundWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 1×
“In the CUS model, repeated exposure to stress over the course of several weeks results in the development of anhedonia, a core symptom of depression, and this effect is reversed by chronic administration of a typical antidepressant (Wilner, 2005; Banasr et al., 2007).”
BackgroundKetamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 5×
“The largest clinical trial of ketamine to date (Murrough et al., 2013) was a two-site, parallel arm, randomized controlled trial of a single infusion of ketamine compared to an active placebo control condition, the anaesthetic midazolam.”
BackgroundMethodResultInfluentialMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 3×
“DiazGranados et al. (2010b) gave 33 subjects with treatment-resistant MDD a single open-label infusion of ketamine (0.5 mg/kg).”
BackgroundResultInfluentialTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 2×
“This has since been replicated in 2 open-label investigations of MDD patients and in one RCT of bipolar patients (Zarate et al. 2012; DiazGranados et al., 2010b; Price et al., 2009).”
ResultMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 5×
“The largest clinical trial of ketamine to date (Murrough et al., 2013) was a two-site, parallel arm, randomized controlled trial of a single infusion of ketamine compared to an active placebo control condition, the anaesthetic midazolam.”
BackgroundMethodResultInfluentialFunctional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 2×
“This has since been replicated in 2 open-label investigations of MDD patients and in one RCT of bipolar patients (Zarate et al. 2012; DiazGranados et al., 2010b; Price et al., 2009).”
BackgroundResultDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 3×
“DiazGranados et al. (2010b) gave 33 subjects with treatment-resistant MDD a single open-label infusion of ketamine (0.5 mg/kg).”
BackgroundResultInfluentialSignaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans
Clements, J. A., Nimmo, W. S., & Grant, I. S. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710516 · Cited by 420 · cited 1×
“Its use had been associated with dissociative reactions on emerging from anaesthesia; however, it remains a desirable anaesthetic because of its short half-life (180 min) and the lack of respiratory depression (Clemens et al. 1982).”
BackgroundKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 2×
“However, given the paucity of randomised controlled trials, lack of an active placebo, limited data on long-term outcomes, ketamine administration is not routinely recommended (Aan het Rot et al. 2012).”
BackgroundA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309 · cited 2×
“Riluzole was administered orally for 28 days to sustained ketamine responders in one study (Mathew et al., 2010) and to all participating MDD patients 4 – 6 h after receiving an IV ketamine infusion in another study (Ibrahim et al., 2012).”
MethodThase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
MacQueen, G. M., Yucel, K., Taylor, V. H., Macdonald, K., & Joffe, R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.027 · Cited by 274 · cited 1×
“These effects could contribute to the reduction in volume of PFC and hippocampus determined by imaging the brains of depressed patients (Drevets and Furey, 2010; Macqueen et al., 2008).”
BackgroundLiu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256 · cited 2×
“A more recent study (Liu et al., 2013) showed that the synaptogenic and antidepressant-like effects of a single otherwise subthreshold dose of ketamine were potentiated when given together with a single dose of lithium chloride (a non-selective GSK-3 inhibitor) or a preferential GSK-3β inhibitor.”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“What is promising is that another low-af fi nity NMDA receptor antagonist, AZD6765, demonstrated antidepressant effects in humans at doses that do not produce psychosis (Zarate et al., 2013).”
BackgroundEntsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241 · cited 3×
“In addition, chronic stress exposure decreases the density of spines in the PFC (Liu and Aghajanian, 2008; Shansky and Morrison, 2009), providing a morphological end-point that can be measured and that is relevant to the atrophy of PFC in depression (Drevets and Furey, 2010).”
BackgroundGlutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Jourdi, H., Hsu, Y.-T., Zhou, M., Qin, Q., Bi, X., & Baudry, M. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6078-08.2009 · Cited by 226 · cited 1×
“…central role in the antidepressant effect of ketamine possibly by increasing BDNF release, TrkB receptor activation, stimulation of mTOR signalling and local protein synthesis (Akin fi resoye and Tizabi, (2013); Jourdi et al., 2009). neurotrophic factor, synapsin, and mammalian target of rapamycin.”
BackgroundAntidepressant-like actions of an AMPA receptor potentiator (LY392098)
Li, X., Tizzano, J. P., Griffey, K., Clay, M., Lindstrom, T., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00194-5 · Cited by 225 · cited 2×
“Several classes of AMPA potentiators, including nootropic agents and ampakines, have shown antidepressant efficacy in preclinical studies (O'Neill et al., 2004; Li et al., 2001) and a number of compounds are currently under clinical development.”
BackgroundThe role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine
Monteggia, L. M., Gideons, E., & Kavalali, E. T. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.006 · Cited by 198 · cited 2×
“Recent studies by Monteggia et al. (2013) show that ketamine effects are dependent on brain-derived neurotrophic factor (BDNF) and subsequent activation of the high-af fi nity BDNF receptor TrkB.”
BackgroundKetamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167 · cited 2×
“This was followed up by a larger open-labeled study more recently (Irwin et al., 2013) where 14 subjects with symptoms of depression or depression mixed with anxiety warranting psychopharmacological intervention received daily oral doses of ketamine hydrochloride (0.”
BackgroundInfluentialMizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145 · cited 1×
“Riluzole is a glutamate-modulating agent with neuroprotective and synaptic plasticity-enhancing properties, used in the treatment of amyotrophic lateral sclerosis (Doble, 1996; Du et al., 2007; Mizuta et al., 2001).”
BackgroundPsychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Ketamine regulates the presynaptic release machinery in the hippocampus
Müller, H. K., Wegener, G., Liebenberg, N., Zarate, C. A., Popoli, M., & Elfving, B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.008 · Cited by 61
Cited by
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
“Although some reviews investigating the effectiveness of ketamine as an emergency treatment have been conducted, often they include only brief mention of the efficacy of ketamine in reducing suicidal ideation in these populations of patients without specific details (Caddy et al., 2015; McCloud et al., 2015; Naughton…”
BackgroundKetamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Li, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152
“Low-dose ketamine results in rapid improvement of depressive symptoms (within 1 h) in patients with treatment-resistant depression (TRD) [Mathew et al., 2012; Naughton et al., 2014].”
BackgroundHu, Y.-D., Xiang, Y.-T., Fang, J.-X., Zu, S., Sha, S., Shi, H., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., Xue, Y., et al. (2016) · Psychological Medicine · doi:10.1017/s0033291715002159 · Cited by 146
“However, although ketamine’s effect has been extended by repeated infusions, the results in relapse prevention have been less than promising (aan het Rot et al. 2010; Murrough et al. 2013b; Naughton et al. 2014).”
Background
Metadata
- Authors
- Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 156
- Pages
- 24-35
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W1999810166
- Cited by
- 190
- References
- 48
- FWCI
- 17.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.